The kinetics of the tissue distribution of silver nanoparticles of different sizes
- PMID: 20684985
- DOI: 10.1016/j.biomaterials.2010.07.045
The kinetics of the tissue distribution of silver nanoparticles of different sizes
Abstract
Blood kinetics and tissue distribution of 20, 80 and 110 nm silver nanoparticles were investigated in rats up to 16 days after intravenous administration once daily for 5 consecutive days. Following both single and repeated injection, silver nanoparticles disappeared rapidly from the blood and distributed to all organs evaluated (liver, lungs, spleen, brain, heart, kidneys and testes) regardless of size. The 20 nm particles distributed mainly to liver, followed by kidneys and spleen, whereas the larger particles distributed mainly to spleen followed by liver and lung. In the other organs evaluated, no major differences between the sizes were observed. Size-dependent tissue distribution suggests size-dependent toxicity and health risks. Repeated administration resulted in accumulation in liver, lung and spleen, indicating that these organs may be potential target organs for toxicity after repeated exposure. A physiologically based pharmacokinetic (PBPK) model for nanoparticles which describes the kinetics of silver nanoparticles was developed. Model parameter values were estimated by fitting to data. No clear relation between parameter values and corresponding particle diameters became apparent.
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration.Biomaterials. 2008 Apr;29(12):1912-9. doi: 10.1016/j.biomaterials.2007.12.037. Epub 2008 Feb 1. Biomaterials. 2008. PMID: 18242692
-
Bioavailability and toxicokinetics of citrate-coated silver nanoparticles in rats.Arch Pharm Res. 2011 Jan;34(1):153-8. doi: 10.1007/s12272-011-0118-z. Epub 2011 Apr 6. Arch Pharm Res. 2011. PMID: 21468927
-
Serum kinetics, distribution and excretion of silver in rabbits following 28 days after a single intravenous injection of silver nanoparticles.Nanotoxicology. 2013 Sep;7(6):1120-30. doi: 10.3109/17435390.2012.710660. Epub 2012 Aug 7. Nanotoxicology. 2013. PMID: 22770226
-
A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity.Crit Rev Toxicol. 2010 Apr;40(4):328-46. doi: 10.3109/10408440903453074. Crit Rev Toxicol. 2010. PMID: 20128631 Review.
-
What do we (need to) know about the kinetic properties of nanoparticles in the body?Regul Toxicol Pharmacol. 2007 Dec;49(3):217-29. doi: 10.1016/j.yrtph.2007.07.006. Epub 2007 Aug 15. Regul Toxicol Pharmacol. 2007. PMID: 17868963 Review.
Cited by
-
Predicting Bioaccumulation of Nanomaterials: Modeling Approaches with Challenges.Environ Health (Wash). 2024 Mar 19;2(4):189-201. doi: 10.1021/envhealth.3c00138. eCollection 2024 Apr 19. Environ Health (Wash). 2024. PMID: 39474143 Free PMC article. Review.
-
Clinical translation and landscape of silver nanoparticles.Drug Deliv Transl Res. 2024 Oct 8. doi: 10.1007/s13346-024-01716-5. Online ahead of print. Drug Deliv Transl Res. 2024. PMID: 39377875
-
Prevention of ventilator-associated pneumonia by metal-coated endotracheal tubes: a meta-analysis.Crit Care. 2024 Sep 17;28(1):309. doi: 10.1186/s13054-024-05095-8. Crit Care. 2024. PMID: 39289732 Free PMC article.
-
Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials.ACS Pharmacol Transl Sci. 2024 Jul 12;7(8):2251-2279. doi: 10.1021/acsptsci.4c00250. eCollection 2024 Aug 9. ACS Pharmacol Transl Sci. 2024. PMID: 39144562 Review.
-
Metal-based nanoparticle in cancer treatment: lessons learned and challenges.Front Bioeng Biotechnol. 2024 Jul 11;12:1436297. doi: 10.3389/fbioe.2024.1436297. eCollection 2024. Front Bioeng Biotechnol. 2024. PMID: 39055339 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources